Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance

Laboratory Investigation

Volumn 79, Issue 6, 1999, Pages 717-722

  Sier, Cornelis F M ^a   Sidenius, Nicolai ^a   Mariani, Andrea ^b   Aletti, Giovanni ^b   Agape, Vittorio ^b   Ferrari, Augusto ^b   Casetta, Giovanni ^c   Stephens, Ross W ^d   Brünner, Nils ^d   Blasi, Francesco ^a,e  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c Institute of Nephro Urology   (Italy)

^d FINSEN LABORATORY   (Denmark)

^e HSRaffaele   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; PLASMINOGEN ACTIVATOR; UROKINASE RECEPTOR;

ARTICLE; CANCER PATIENT; CELL MIGRATION; CONTROLLED STUDY; CREATININE URINE LEVEL; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GYNECOLOGIC CANCER; HUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; QUANTITATIVE ASSAY; URINALYSIS;

ADULT; AGED; CREATININE; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL DISEASES, FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INFERTILITY, FEMALE; LEIOMYOSARCOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; RECURRENCE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; UTERINE PROLAPSE;

EID: 0033049540     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Andreasen PA, Kjøller L, Christensen L, and Duffy MJ (1997). The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72:1-22.
2. Behrendt N and Stephens RW (1998). The urokinase receptor. Fibrinol Protol 12:191-204.
3. Blasi F (1997). uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18:1121-1123.
4. Casslén B, Gustavsson B, and Åstedt B (1991). Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer 27: 1445-1448.
5. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, and Skriver L (1985). Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44:139-266.
6. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, and Blasi F (1997). The urokinase sensitive region of the urokinase receptor is responsible for its potent chemotactic activity. EMBO J 16:7279-7286.
7. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CBHW, and Verspaget HW (1994). Urokinase receptor and colorectal cancer survival. Lancet 344:401-402.
8. Ganesh S, Sier CFM, Heerding MM, Van Krieken JHJM, Griffioen G, Van de Velde, CJH, Verheijen JH, Lamers CBHW, and Verspaget HW (1996). Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 77:1035-1043.
9. Grøndahl-Hansen J, Peters HA, Van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, and Foekens JA (1995). Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1:1079-1087.
10. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, and Danø K (1997). Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 243:21-26.
11. Pedersen N, Brünner N, Francis D, Østerlind K, Rønne E, Høi-Hansen H, Danø K, and Grøndahl-Hansen J (1994). Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54:4671-4675.
12. Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, Giavazzi R, Danø K, Kuhn W, Jänicke F, and Blasi F (1993). A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92:2160-2167.
13. Ploug M, Østergaard S, Hansen LB, Holm A, and Danø K (1998). Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist: Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 37:3612-3622.
14. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, and Fazioli F (1996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15:1572-1582.
15. 2-terminal domain of the urokinase receptor. FEBS Lett 288:233-236.
16. Sier CFM, Quax PHA, Vloedgraven HJM, Verheijen JH, Griffioen G, Ganesh S, Lamers CBHW, and Verspaget HW (1993). Increased urokinase receptor levels in human gastro-intestinal neoplasia and related liver metastases. Invasion Metastasis 13:277-288.
17. Sier CFM, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, and Blasi F (1998). The level of urokinase type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58:1843-1849.
18. Solberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K, and Høyer-Hansen G (1994). A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors, Int J Cancer 58:877-881.
19. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJAG, Høyer Hansen G, Rønne E, Dybkjær E, Danø K, and Brünner N (1997). ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876.
20. Stump DC, Thienpont M, Collen D (1986). Purification and characterization of novel inhibitor of urokinase from urine. J Biol Chem 261:12759-12766.
21. Williams JRB (1951). The fibrinolytic activity of urine. Br J Exp Pathol 32:530-537.